MedTrace Logo

Effects of Hallucinogens and Other Drugs on Mood and Performance

NCT02033707 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2019-05-16

No results posted yet for this study

Summary

This non-treatment study will investigate the effects on mood and performance caused by hallucinogens and other psychoactive compounds.

Conditions

  • Healthy

Interventions

DRUG

Hallucinogens and psychoactive substances

One of the following or placebo will be given: Hallucinogens: DMT, 4-phosphoryloloxy-N-diethyltryptamine, dipropyltryptamine (DPT), ketamine, dextromethorphan, mescaline, PCP, psilocybin, salvinorin-A, LSD, d-lysergic acid amide (LSA), MDMA, cannabis Sedatives/anxiolytics: alprazolam, diazepam, lorazepam, secobarbital, temazepam, triazolam, zolpidem Antihistamines: diphenhydramine, chlorpheniramine Stimulants: d-amphetamine, caffeine, ephedrine, methylphenidate, diethylproprion Opioids: heroin, morphine, oxycodone, hydrocodone, methadone, codeine Other: alcohol, scopolamine, nicotine Each volunteer will receive a hallucinogen on at least one of five sessions. More drugs are listed than will be administered to increase the degree to which volunteers are "blind" to the drugs being studied. It is important that the volunteer and research staff be blinded to specific drug conditions to minimize confounding the results with expectations about the nature of drug effects.

Sponsors & Collaborators

Principal Investigators

  • Roland R Griffiths, Ph.D. · Johns Hopkins University

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2019-02-28
Completion
2019-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02033707 on ClinicalTrials.gov